1. Tamoxifen versus cyclophosphamide, Adriamycin, and 5-fluorouracil plus either concurrent or sequential tamoxifen in postmenopausal, receptor positive node, node-positive breast cancer: A Southwest Oncology Group Phase III intergroup trial;Albain;Proceedings of the American Society of Clinical Oncology,1997
2. HER-2/ neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma;Allred;J Clin Oncol,1992
3. Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer. Adopted on November 7, 1997, by the American Society of Clinical Oncology;American Society of Clinical Oncology;J Clin Oncol,1998
4. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma;Ayash;J Clin Oncol,1998
5. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications;Baselga;Oncology,1997